Thera-SAbDab

BEZLOTOXUMAB

>   Structural Summary
TherapeuticBezlotoxumab
TargetToxin A
Heavy ChainEVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK
100% seqID Fv Structure4np4 [Fvs: HL, IM]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)NFD
Recorded Developmental TechnologyMedarex HuMAb Mouse
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedMedarex, University of Massachusetts Medical School, Merck & Co, Merck Sharp & Dohme
Conditions ApprovedClostridium difficile
Conditions Activena
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]